88 related articles for article (PubMed ID: 29923286)
1. Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy.
Kazierad DJ; Chidsey K; Somayaji VR; Bergman AJ; Calle RA
Diabetes Obes Metab; 2018 Nov; 20(11):2608-2616. PubMed ID: 29923286
[TBL] [Abstract][Full Text] [Related]
2. A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.
Bergman A; Tan B; Somayaji VR; Calle RA; Kazierad DJ
Diabetes Res Clin Pract; 2017 Apr; 126():95-104. PubMed ID: 28237861
[TBL] [Abstract][Full Text] [Related]
3. Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.
Kazierad DJ; Bergman A; Tan B; Erion DM; Somayaji V; Lee DS; Rolph T
Diabetes Obes Metab; 2016 Aug; 18(8):795-802. PubMed ID: 27059951
[TBL] [Abstract][Full Text] [Related]
4. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.
Pettus JH; D'Alessio D; Frias JP; Vajda EG; Pipkin JD; Rosenstock J; Williamson G; Zangmeister MA; Zhi L; Marschke KB
Diabetes Care; 2020 Jan; 43(1):161-168. PubMed ID: 31694861
[TBL] [Abstract][Full Text] [Related]
6. Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.
Gumbiner B; Esteves B; Dell V; Joh T; Garzone PD; Forgie A; Udata C
Endocrine; 2018 Nov; 62(2):371-380. PubMed ID: 30203123
[TBL] [Abstract][Full Text] [Related]
7. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
Amin NB; Aggarwal N; Pall D; Paragh G; Denney WS; Le V; Riggs M; Calle RA
Diabetes Obes Metab; 2015 Aug; 17(8):751-9. PubMed ID: 25885172
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study.
Ji L; Li L; Ma J; Li X; Li D; Meng B; Lu W; Sun J; Liu Y; Takayanagi G; Wang Y
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00222. PubMed ID: 33855222
[TBL] [Abstract][Full Text] [Related]
10. A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*.
Terra SG; Somayaji V; Schwartz S; Lewin AJ; Teeter JG; Dai H; Nguyen TT; Calle RA
Exp Clin Endocrinol Diabetes; 2011 Jul; 119(7):401-7. PubMed ID: 21472661
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
14. Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Dobbins R; Hussey EK; O'Connor-Semmes R; Andrews S; Tao W; Wilkison WO; Cheatham B; Sagar K; Hanmant B
BMC Pharmacol Toxicol; 2021 Jun; 22(1):34. PubMed ID: 34120651
[TBL] [Abstract][Full Text] [Related]
15. Antisense Inhibition of Glucagon Receptor by IONIS-GCGR
Morgan ES; Tai LJ; Pham NC; Overman JK; Watts LM; Smith A; Jung SW; Gajdošík M; Krššák M; Krebs M; Geary RS; Baker BF; Bhanot S
Diabetes Care; 2019 Apr; 42(4):585-593. PubMed ID: 30765435
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Kazda CM; Ding Y; Kelly RP; Garhyan P; Shi C; Lim CN; Fu H; Watson DE; Lewin AJ; Landschulz WH; Deeg MA; Moller DE; Hardy TA
Diabetes Care; 2016 Jul; 39(7):1241-9. PubMed ID: 26681715
[TBL] [Abstract][Full Text] [Related]
18. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
20. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
Kazda CM; Frias J; Foga I; Cui X; Guzman CB; Garhyan P; Heilmann C; Yang JA; Hardy TA
Diabetes Obes Metab; 2017 Aug; 19(8):1071-1077. PubMed ID: 28191913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
